Search Clinical Trials

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

168 results

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

The purpose of the study is to compare any good and bad effects of using a combination of the investigational agents cediranib and olaparib, to using the standard chemotherapy, or cediranib alone, or olaparib alone.
Protocol No
NRG-GY005
Sub Category
Gynecologic Cancers

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5%.
Protocol No
NRG-CC003
Sub Category
Brain and Spine Cancers
Thoracic Cancers

GALACTIC

To evaluate the safety and efficacy of treatment with omecamtiv mecarbil (OM) on Mortality and Morbidity in patients with Chronic Heart Failure with Reduced Ejection Fraction

Primary Investigator: Michell Saltzberg, MD
Subinvestigators:  Nicole Lohr, MD, PhD
 

Sub Category
Advanced Heart Failure

ADAPTRESPONSE Clinical Trial (AdaptivCRT Therapy vs Standard CRT Therapy)

To determine if market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT(aCRT) algorithm have a superior outcome compared to standard CRT devices in patients with normal AV conduction and Left Bundle Branch Block.

Primary Investigator: Marcie Berger, MD
Subinvestigators: Jason Rubenstein, MD, James Oujiri, MD, James Roth, MD, Nicole Lohr, MD, PhD

Status: Currently enrolling

Sub Category
Advanced Heart Failure
Share This: